Hexarelin is a synthetic six-amino-acid peptide that triggers the pituitary to release its own growth hormone, and it is not an approved medicine anywhere in the United States. The honest bottom line is narrow: the acute growth hormone pulse is real and well characterized in short pharmacology studies, while nearly everything downstream of it rests on animal models, mechanism, or inference. Material sold under this name is handled as a research chemical, which means the pharmacology and the product quality are two separate risks.
Hexarelin is a synthetic hexapeptide growth hormone secretagogue acting as an agonist at the GHS-R1a ghrelin receptor, and it holds no FDA approval for any medical indication in the United States.
Hexarelin supplies no growth hormone of its own; it prompts the pituitary to release what it has already stored. The route runs through GHS-R1a, the receptor that evolved for ghrelin, which is why a peptide studied for the growth hormone axis also reaches appetite signaling and the cardiovascular system. That borrowed pathway is the single fact that explains most of what follows on this page.
Hexarelin is a ghrelin mimetic that raises circulating growth hormone within minutes of a single administration, with the pulse peaking at roughly 15 to 30 minutes before returning toward baseline.
The benefit list attached to Hexarelin in the market runs considerably longer than the evidence behind it. One effect is documented well: a strong, dose-dependent growth hormone release that raises insulin-like growth factor 1 through the liver. Almost everything sold downstream of that, from recovery to body composition, is inference from what growth hormone does rather than a measured outcome of this peptide.
Hexarelin's dose-dependent growth hormone release and the resulting IGF-1 elevation are its only well-documented effects in humans, and no controlled long-duration human trial has established physique, performance, or recovery outcomes.
Every number published for Hexarelin comes from experimental characterization, not from a validated treatment regimen, and the peptide carries no approved dose in any country. The short circulating half-life, measured in tens of minutes, is why study protocols aiming to mimic natural pulsatility split the daily amount across more than one administration rather than a single large dose.
Clinical pharmacology studies characterized Hexarelin at fixed doses on the order of one to two micrograms per kilogram, a research probe of the growth hormone response rather than an approved therapeutic dose.
Hexarelin has no safety record in the regulatory sense of the term. What exists is limited study exposure with no post-market surveillance behind it, because the compound was never approved and never followed in a treated population. The documented hazards split cleanly into what the pharmacology predicts and what the supply chain adds on top.
Hexarelin raises cortisol and prolactin alongside growth hormone and reduces insulin sensitivity, and its long-term safety has never been characterized in a controlled long-duration human trial.
Potency and cleanliness pull in opposite directions across this family, and Hexarelin sits at the potent, untidy end of it. The peptides that came later trade raw growth hormone output for a narrower hormonal footprint, and that trade is what separates the compounds far more than any difference in headline potency.
| Criteria | Hexarelin | Ipamorelin | MK-677 |
|---|---|---|---|
| Acute GH pulse | Among the strongest early GHRPs | Lower raw potency | Sustained daily elevation |
| Cortisol and prolactin | Tends to rise | Minimal | Minimal |
| Appetite stimulation | Present, less than GHRP-6 | Little | Marked |
| Duration | Short, sharp pulse | Short pulse | Long half-life, orally active |
| Desensitization | Rapid with repeated dosing | Responsiveness better preserved | Sustained exposure |
Hexarelin produces one of the strongest acute growth hormone pulses among the early growth hormone releasing peptides but is less selective than Ipamorelin and desensitizes faster, which is why the literature positions it for short investigational courses rather than sustained use.
The research-chemical label on a vial is a distribution convention, not a regulatory clearance. Hexarelin has not been approved by the US Food and Drug Administration for any indication and is not available as a prescription medicine in the United States, and the not-for-human-use wording is precisely what keeps it outside the drug approval and pharmacy systems. Exposure past that point depends on who holds the vial and where.
Hexarelin holds no FDA approval for any medical indication in the United States and is prohibited in sport at all times under the World Anti-Doping Agency prohibited list.
The cardiovascular file is the part of Hexarelin's record that genuinely surprised the field, because the heart effects turn up where growth hormone is not the mediator. That decoupling is what drove the interest, and it is also where the evidence stops: the signal comes overwhelmingly from laboratory and animal work, not from large controlled human trials.
Hexarelin's cardioprotective activity is demonstrated in animal models and appears to run through cardiac growth hormone secretagogue receptors and the CD36 receptor rather than growth hormone itself, leaving it investigational rather than a validated cardiac treatment in people.
Tolerance is the constraint that shapes everything else about how Hexarelin gets used. Under repeated stimulation the growth hormone secretagogue receptor is internalized and its signaling downregulated, so the pulse a first exposure produces shrinks with each one that follows. A compound whose signature effect fades cannot hold the growth hormone axis up over time, and that limitation, more than any single side effect, is what caps its usefulness against longer-acting alternatives.
Hexarelin's growth hormone response diminishes over days to weeks of continuous dosing as the growth hormone secretagogue receptor is internalized and downregulated, which is why the research literature describes short or intermittent courses rather than sustained daily administration.
Potency at GHS-R1a is not selective potency. The same receptor engagement that makes Hexarelin's growth hormone pulse large also pulls adrenocorticotropic hormone and prolactin along with it, which is the specific gap that later peptides were designed to close.
Hexarelin raises cortisol through adrenocorticotropic hormone release and increases prolactin alongside growth hormone, a broader hormonal footprint than selective agents such as Ipamorelin, which were designed specifically to avoid it.
Educational use only. This article describes what the published scientific and clinical literature reports about Hexarelin. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
